Actualités Sema4 Holdings Corporation - SMFRW | Actions NASDAQ

Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform

Business combination projected to deliver $350 million in pro forma 2022 revenue $200 million private...

Sema4 Announces Preliminary Revenue for the Fourth Quarter and Fiscal Year 2021

STAMFORD, Conn., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical...

Sema4 to Participate at the 40th Annual J.P. Morgan Healthcare Conference in January

STAMFORD, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical...

Sema4 Reports Third Quarter 2021 Financial Results and Business Highlights

36% increase in test volume (excluding COVID-19 tests) compared to the same period last year 17% growth in...

Sema4 and Mount Sinai use Machine Learning to Improve Postpartum Hemorrhage Risk Prediction

STAMFORD, Conn., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ: SMFR), an AI-driven genomic and clinical...

Sema4 to Participate at Three Upcoming Investor Conferences in November

STAMFORD, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical...

Sema4 to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021

STAMFORD, Conn., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical...

Sema4 Appoints Computational Biology Expert Gustavo Stolovitzky as Chief Science Officer

STAMFORD, Conn., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sema4, an AI-driven genomic and clinical data...

Sema4 Launches Sema4 Elements™, a Portfolio of Data Science-Driven Products and Services to Support Reproductive and Generational Health

STAMFORD, Conn., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sema4, an AI-driven genomic and clinical data...

Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform Company

Sema4 Holdings Corp (“Sema4”) to debut on Nasdaq as a publicly traded company dedicated to transforming...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Sema4 Holdings Corporation (SMFRW)

Votre Hub pour des idées et discussions en direct en temps réel

SMFRW Actualités

Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform

Sema4 Announces Preliminary Revenue for the Fourth Quarter and Fiscal Year 2021

Sema4 to Participate at the 40th Annual J.P. Morgan Healthcare Conference in January

Sema4 Reports Third Quarter 2021 Financial Results and Business Highlights

Sema4 and Mount Sinai use Machine Learning to Improve Postpartum Hemorrhage Risk Prediction

Sema4 to Participate at Three Upcoming Investor Conferences in November

Sema4 to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021

Sema4 Appoints Computational Biology Expert Gustavo Stolovitzky as Chief Science Officer

Sema4 Launches Sema4 Elements™, a Portfolio of Data Science-Driven Products and Services to Support Reproductive and Generational Health

Sema4 to Participate at Two Upcoming Investor Conferences in September

Sema4 Reports Second Quarter 2021 Financial Results and Business Highlights

Avera Health and Sema4 Announce Collaboration to Advance Precision Oncology Care

Sema4 to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021

Sema4 to Participate at Two Upcoming Investor Conferences in August

Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform Company

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Sema4 Holdings Corporation (SMFRW) Actualités

Sema4 Holdings Corporation (SMFRW)

Votre Hub pour des idées et discussions en direct en temps réel

SMFRW Actualités

Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform

Sema4 Announces Preliminary Revenue for the Fourth Quarter and Fiscal Year 2021

Sema4 to Participate at the 40th Annual J.P. Morgan Healthcare Conference in January

Sema4 Reports Third Quarter 2021 Financial Results and Business Highlights

Sema4 and Mount Sinai use Machine Learning to Improve Postpartum Hemorrhage Risk Prediction

Sema4 to Participate at Three Upcoming Investor Conferences in November

Sema4 to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021

Sema4 Appoints Computational Biology Expert Gustavo Stolovitzky as Chief Science Officer

Sema4 Launches Sema4 Elements™, a Portfolio of Data Science-Driven Products and Services to Support Reproductive and Generational Health

Sema4 to Participate at Two Upcoming Investor Conferences in September

Sema4 Reports Second Quarter 2021 Financial Results and Business Highlights

Avera Health and Sema4 Announce Collaboration to Advance Precision Oncology Care

Sema4 to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021

Sema4 to Participate at Two Upcoming Investor Conferences in August

Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform Company

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application